Back

Advancing AML Treatment: Prof. Arnon Nagler’s Key Insights from EBMT 2024

Prof. Arnon Nagler's interview at EBMT highlighted evolving strategies in bone marrow transplantation, emphasizing tailored donor selection and immunosuppression methods.

Prof. Arnon Nagler’s interview at EBMT highlighted evolving strategies in bone marrow transplantation, emphasizing tailored donor selection and immunosuppression methods.

Last month, Prof. Arnon Nagler, President of the Hemato-Oncology Center at Sheba, was invited to the 50th annual meeting of the European Society of Blood and Marrow Transplantation (EBMT). The event was held in Glasgow, Scotland, and was attended by more than 5,500 guests from across the medical sphere, including nurses, physicians, data managers, statisticians, quality managers, cell therapists, pediatricians, pharmacists, psychologists, psychoanalysts, transplant coordinators, lab scientists, trainees and even patients. 

In an event characterized by dialogue, an exchange of information, education and scientific productivity, Prof. Nagler was interviewed and spoke in depth on the evolving strategies within haploidentical bone marrow transplantation. 

He also discussed the nuanced approach required for donor selection criteria, highlighting the importance of tailoring these criteria based on the chosen immunosuppression method, whether it be anti-thymocyte globulin (ATG) or post-transplantation cyclophosphamide (PTCy). 

Furthermore, Prof. Nagler underscored the pivotal role of PTCy in mitigating graft-versus-host disease (GvHD) following transplantation, noting its potential synergy when combined with ATG for enhanced efficacy. He also shed light on the benefits of non-myeloablative conditioning, particularly for older AML patients undergoing haplo-SCT, as it offers a more tolerable treatment regimen while maintaining therapeutic effectiveness.

Prof. Nagler’s interview is a must-watch for anyone interested in the latest advancements in AML treatment and bone marrow transplantation, as he provides a comprehensive overview of key strategies and considerations, offering valuable insights into improving patient outcomes.

Watch Prof. Nagler’s full interviews here